Denali Therapeutics Inc. (DNLI) Net income 2016–2025
Denali Therapeutics Inc. (DNLI) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$512.5MFY2025 · since FY2016: -$86.7M → -$512.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$512.5M | -21.2% |
| FY2024 | -$422.8M | -191.1% |
| FY2023 | -$145.2M | +55.5% |
| FY2022 | -$326.0M | -12.2% |
| FY2021 | -$290.6M | -508.5% |
| FY2020 | $71.1M | +136.0% |
| FY2019 | -$197.6M | -445.3% |
| FY2018 | -$36.2M | +58.9% |
| FY2017 | -$88.2M | -1.8% |
| FY2016 | -$86.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DNLI financial trends
DNLI RevenueDNLI Net marginDNLI Gross profitDNLI Gross marginDNLI Operating incomeDNLI Operating marginDNLI Operating cash flowDNLI Free cash flowDNLI Capital expendituresDNLI Return on equityDNLI Stock buybacksDNLI Dividends paidDNLI Total assetsDNLI Total liabilitiesDNLI Shareholders’ equityDNLI overview →